Article Text

Extended report
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
  1. P J Mease1,
  2. R Fleischmann2,
  3. A A Deodhar3,
  4. J Wollenhaupt4,
  5. M Khraishi5,
  6. D Kielar6,
  7. F Woltering7,
  8. C Stach7,
  9. B Hoepken7,
  10. T Arledge8,
  11. D van der Heijde9
  1. 1Swedish Medical Center and University of Washington, Seattle, Washington, USA
  2. 2University of Texas SW Medical Center, Dallas, Texas, USA
  3. 3Div Arthritis/Rheumatic Diseases (OPO9), Oregon Health & Science University, Portland, Oregon, USA
  4. 4Klinik für Rheumatologie und klinische Immunologie, Schoen Klinik, Hamburg, Germany
  5. 5Memorial University of Newfoundland, Nexus Clinical Research, St. John's, Newfoundland and Labrador, Canada
  6. 6UCB Pharma, Brussels, Belgium
  7. 7UCB Pharma, Monheim am Rhein, Germany
  8. 8UCB Pharma, Raleigh, North Carolina, USA
  9. 9Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  1. Correspondence to Professor Philip J Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA, 98122, USA; pmease{at}philipmease.com

Statistics from Altmetric.com

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles